Rejection of tumors of the B cell lineage by idiotype-vaccinated mice.
Idiotypic determinants of immunoglobulins of malignant B lymphocytes and plasma cells are tumor-specific antigens and have been used extensively in immunotherapy studies. The mechanisms involved in resistance to tumor challenge following idiotype vaccination are poorly understood. Although a predominant role has been attributed to anti-idiotype antibodies, both humoral and cellular immune responses are probably involved. Cell-mediated responses may be particularly effective against tumor cell variants that do not express the idiotype on the cell surface and are therefore resistant to anti-idiotype antibodies but continue to produce one of the original immunoglobulin polypeptides that may be processed and presented to T cells. In this report we describe two experimental models of idiotype vaccination in which antibodies are unlikely to play a role, and hence tumor immunity is attributed to cell-mediated responses. One model consists of the murine B lymphocyte tumor 38C-13 and its idiotype-negative variant DB2, which has lost the idiotypic specificity of the parental 38C-13 cell line through the production of a different light chain but expresses the original heavy chain. Vaccination of mice with the purified IgM of 38C-13 induced resistance to 38C-13 tumor cells as well as to the variant cells. Although immunized mice produced high levels of anti-idiotype antibodies that bound to 38C-13 cells, no binding of antibodies to DB2 cells occurred. The finding that idiotype-vaccinated mice were resistant to idiotype-negative DB2 cells suggested that cellular mechanisms are involved in mediating resistance. The second model consists of the two plasma cell line JLmu s and JLmu m, which produce IgM with an identical specificity. Whereas one of them (JLmu s) secretes the IgM, the other one (JLmu m) can neither secrete nor deposit it on the cell surface. Immunization against JLmu s IgM followed by tumor challenge resulted in prolonged survival of both JLmu s- and JLmu m-challenged mice. Although sera of immunized mice contained high levels of anti-idiotype antibodies, they did not react with the plasmacytoma cells. Similarly to the results obtained in the 38C-13 experimental model, these results suggest that a non-antibody-mediated mechanism was involved in the resistance of mice to tumor growth.
Haimovich
J
J
Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Israel.
Kukulansky
T
T
Weissman
B
B
Hollander
N
N
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology*; D019070:Cell Lineage; D006433:Hemocyanins / Q000276:immunology; D007111:Immunity, Cellular / Q000276:immunology; D018796:Immunoconjugates / Q000276:immunology; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology* / Q000378:metabolism; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D010954:Plasmacytoma / Q000276:immunology* / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines; D018796:Immunoconjugates; D007130:Immunoglobulin Idiotypes; D007075:Immunoglobulin M; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin